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Abstract Improper eating habits such as high-fat or high-
carbohydrate diets are responsible for metabolic changes
resulting in impaired glucose tolerance, hyperinsulinemia,
insulin resistance, and ultimately diabetes. Although the es-
sentiality of trivalent chromium for humans has been recently
questioned by researchers, pharmacological dosages of this
element can improve insulin sensitivity in experimental ani-
mals and diabetic subjects. The aim of the study was to assess
the preventive potential of the supplementary chromium(III)
propionate complex (CrProp) in rats fed a high-fat diet. The
experiment was conducted on 32maleWistar rats divided into
four groups and fed the following diets: the control (C, AIN-
93G), high-fat diets (HF, 40% energy from fat), and a high-fat
diet supplemented with CrProp at dosages of 10 and
50 mg Cr/kg diet (HF+Cr10 and HF+Cr50, respectively).
After 8 weeks, high-fat feeding led to an increased body mass,
hyperinsulinemia, insulin resistance, a decreased serum urea
concentration, accumulation of lipid droplets in hepatocytes,
and increased renal Fe and splenic Cu contents. Supplemen-
tary CrProp in both dosages did not alleviate these changes but
increased renal Cr content and normalized splenic Cu content
in high-fat-fed rats. Supplementary CrProp does not prevent
the development of insulin resistance in rats fed a high-fat diet.
Keywords Chromium(III) propionate complex . Insulin
resistance . High-fat diet . Rats
Introduction
According to the forecast of the International Diabetes Feder-
ation, in the year 2030, the number of diabetics is expected to
rise to 552 million worldwide [1]. Studies have shown that
insulin resistance, defined as an impaired responsiveness of
the body to insulin, is a prediabetic stage associated with
obesity, leading to type 2 diabetes [2]; thus, it is believed that
early identification and treatment of individuals with predia-
betes can delay the progression of full-blown diabetes and
related complications [3].
Chromium(III) is a dietary component involved in glucose
metabolism, and for over 50 years, it has been considered as
an essential element for mammals, including humans.
Chromium(III) has a documented role in carbohydrate, lipid,
and protein metabolisms [4]. Trivalent chromium has been
shown to lower oxidative stress and improve glucose and lipid
metabolism; however, the mechanism of its action on the
molecular level is not fully understood yet.
Cr(III) supplements have become very popular commercial
dietary supplements worldwide, advertised for reducing body
mass and improving blood glucose control, especially for
diabetic subjects. However, most of these claims were not
supported in well-controlled studies. Recently, the “essential-
ity” of chromium has been questioned due to its ubiquitous
nature, very low dietary requirement [5], and a lack of a
reliable marker [6].
The major doubt came from the results of a study per-
formed in Vincent’s laboratory [5]. The authors fed male
Zucker lean rats the AIN-93G diet with no added chromium
in the mineral mix component of the diet (low-Cr diet—
16 μg/kg), the standard AIN-93G diet (1,135 μg/kg), the
standard AIN-93G diet supplemented with 200 μg Cr/kg
(1,331 μg/kg), or the standard AIN-93G diet supplemented
with 1,000 μg Cr/kg (2,080 μg/kg) for 6 months. It turned out
that the chromium content of the diet had no effect on body
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mass or food intake, and serum glucose levels in glucose
tolerance or insulin tolerance tests. The studies revealed that
a diet with as little chromium as reasonably possible had no
effect on body composition, glucose metabolism, or insulin
sensitivity compared with a chromium-“sufficient” diet.
Based on these observations, the authors concluded that chro-
mium can no longer be considered an essential element.
The history of biochemical and nutritional studies of Cr has
been broadly reviewed by Vincent and Love [7] and will not
be repeated in detail in this article.
If Cr is not an essential element for mammals, but at certain
dosages modulates glucose and lipids homeostasis, its actions,
still not fully understood, could be called “pharmacological.”
Among the various chemical forms of Cr(III) including
those used in dietary supplements, the Cr(III) propionate
complex (CrProp) [Cr3O(O2CCH2CH3)6(H2O)3]
+, also called
Cr3, is of particular interest. Most results concerning the
properties and biological activity of this compound come from
Vincent’s laboratory [8–10].
In our previous studies [11–13], we showed using various
animal models that CrProp, given at dosages of 1 and
5 mg/kg body mass (b.m.)/day, has a significant insulin-
sensitizing antidiabetic potential. The therapeutic properties
of CrProp in relation to its antidiabetic, insulin-sensitizing
potential were discussed in previous publications [9, 11, 12].
The objective of this study was to examine the preventive
potential of supplementary CrProp, given at dosages of 10 and
50 mg Cr/kg diet, against insulin resistance induced naturally
by feeding rats a high-fat diet.
Materials and Methods
Animals and Diets
The experiment was carried out according to the Animal
Welfare Standards. All the procedures used in this study were
accepted by the Animal Bioethics Committee of Poznan,
Poland (approval no. 59/2005).
Eight-week-old male Wistar rats (n=32) with body weight
ranging from 188 to 248 g were purchased at the Licensed
Laboratory Animal Breeding Center (Poznan, Poland). Dur-
ing both the adaptation and the experimental period, animals
were housed under controlled temperature (21±2 °C), humid-
ity (55–60 %), and with a 12 h/12 h day/night cycle. After
5 days of the adaptation period, animals were divided into four
groups of eight rats each and kept individually in metal-free
individual cages. Animals were fed ad libitum standard and
high-fat diets composed according to the AIN-93G recom-
mendations [14] of casein (20 %), sunflower oil (7 %), wheat
starch (53.2 %), sucrose (10 %), potato starch (5 %), L-
cysteine (0.3 %), vitamin mix AIN-93M (1 %), and mineral
mix AIN-93M (3.5 %). The high-fat diets (HF) were obtained
from the basal AIN-93 diet, by replacement of wheat starch
with fat (up to 25 %, approximately 40 % energy from fat).
Supplementary Cr was given in the form of CrProp at dosages
of 10 and 50 mg Cr/kg diet, so the diets had variable levels of
Cr, such as C (control, 2 mgCr/kg), HF (high fat, 2 mg Cr/kg),
HF+Cr10 (high fat, 10 mg Cr/kg), and HF+Cr50 (high fat,
50mgCr/kg). Diets were prepared once a week and stored in a
refrigerator. Food intake was monitored daily and body mass
gain weekly. The chemical composition of experimental diets
is presented in Table 1.
Test Chemicals
The source of supplemental Cr(III) was CrProp (chemical
formula [Cr3O(O2CCH2CH3)6(H2O)3]
+(NO3), called Cr3),
added to the mineral mix to obtain 1, 10, and 50 mg Cr/kg
diet. The compound was synthesized at the laboratory of the
Department of Product Ecology, Poznan University of Eco-
nomics, according to the method described previously by
Earnshaw et al. [15]. The content of Cr in mineral mix and
diets was assured by the atomic absorption spectroscopy
(AAS) method (an AAS-3 spectrometer with background
correction (BC), Zeiss, Germany). The authenticity was
established using the physicochemical characteristics of
CrProp as described previously [16]. The addition of CrProp
to diets has no impact on feed palatability.
Data Collection
At the end of the experiment, after 16-h fasting, rats were
anesthetized with an intraperitoneal thiopental injection
(35 mg/kg b.m.) and dissected to collect blood from the aorta
Table 1 Chemical composition of diets used in experiment (mean±SD)
Ingredient C Diets
HF HF+Cr10 HF+Cr50
Energy (MJ, 100 g) 1.83±0.01 2.27±0.02 2.28±0.03 2.29±0.02
Protein (%) 18.7±1.23 17.5±0.14 17.7±036 17.9±0.13
Fat (%) 7.14±0.31 25.4±1.07 26.4±0.21 26.4±0.08
Carbohydrates (%) 61.7 47.9 46.9 46.2
Dry mass (%) 91.8±0.19 93.7±0.31 94.0±0.32 93.5±0.18
Ash (%) 4.06±0.71 2.89±0.23 2.99±0.11 2.90±0.12
Cr (μg/g) 2.01±0.51 2.10±0.28 10.1±0.79 50.4±4.71
C control (AIN-93G),HFhigh-fat,HF+Cr10high-fat with Cr (10 mg/kg
diet), HF+Cr50 high-fat with Cr (50 mg/kg diet)
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and remove inner organs (liver, kidneys, heart, spleen, pan-
creas, testes) for appropriate biochemical tests. Organs were
washed in saline, weighed, and stored at −20 °C until
analyzed.
Blood Biochemistry
Blood serum indices were determined by the following
methods: glucose concentration by the hexokinase method
[17] and total, LDL, and HDL cholesterol contents and
triacylglycerol (TAG) concentrations by the colorimetric
methods [18–20] using Olympus AU 560 equipment.
Plasma insulin concentration was measured by the RIA
method using a kit specific for rats (Linco Research, St.
Charles, MO, USA).
Activity of alanine transaminase (ALT) and aspartate
transaminase (AST) enzymes was measured by the ki-
netic methods [21], while urea concentration by the
kinetic method using urease and glutamine dehydroge-
nase, and creatinine concentration by Jaffe’s kinetic
method with picric acid [22]. The total protein concen-
tration was determined by the colorimetric method using
Cu+2 ions [23].
The efficacy of glucose utilization and insulin resistance
was characterized by the homeostasis model assessment
(HOMA) indices [24].
HOMA‐IR ¼ Fasting glucose mmol=dm3  Fasting insulin mIU=dm3  =22:5
Histology of the Liver and the Kidney
A 3- to 5-mm section of the representative tissue (liver and
kidney) was collected at the time of sacrifice and preserved in
10 % buffered formalin. Sections were processed by standard
histologic methods and embedded in paraffin. Slices were
prepared and stained with hematoxylin and eosin [25].
Microelement Determinations
Organs were digested in 65 % (w/w) spectra pure HNO3
(Merck) in the Microwave Digestion System (MARS 5,
CEM). Then, the concentrations of Fe, Zn, and Cu in the
mineral solutions were measured by the F-AAS method
(AAS-3 spectrometer, Zeiss, with BC, Germany), while Cr
content was determined by the graphite furnace AAS method
(AA EA 5 spectrometer, with BC, Jenoptic, Germany).
The accuracy of quantitative determinations of Fe, Zn, Cu,
and Cr was assured by simultaneous analyses of the certified
reference material (Pig Kidney BCR® No. 186, Brussels,
fortified with Cr standard).
Statistical Analysis
All results are presented as arithmetic means±standard devi-
ation, and significance of differences in means was calculated
using the one-way ANOVA and Tukey’s test. Means were
considered statistically different at p<0.05. All calculations




Feeding rats with high-fat diets resulted in the slightly increas-
ing body weight gain and the significantly increasing body
mass/body length ratio (by 10 %), but it did not affect relative
internal organ masses. Generally, supplementary CrProp did
not affect overall growth indices in rats fed a high-fat diet;
however, in CrProp-supplemented rats, relative liver mass
tended to decrease (Table 2).
Insulin Resistance and Lipid Indices
Table 3 presents the effects of high-fat diet and supplementary
CrProp on biochemical indices in rats. Feeding rats a high-fat
diet (40 % energy from fat) did not affect serum lipid indices
or glucose levels, but it induced insulin resistance as evi-
denced by the twofold increased serum insulin level and
homeostasis model assessment-estimated insulin resistance
(HOMA-IR) index. Supplementary CrProp (in both dosages)
did not influence glucose metabolic indices (glucose, insulin
level, and HOMA-IR index) in rats fed high-fat diets. Serum
lipid profile was also unchanged, with exception to serum
TAG that tended to decrease in CrProp-supplemented groups.
Toxicity Indices and Histology of the Liver and the Kidney
Feeding neither a high-fat diet nor supplementary CrProp (in
both dosages) significantly affected indices of liver damage
(serum ALT and AST activity) or serum creatinine levels,
whereas the high-fat diet significantly decreased serum urea
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concentration by 16 %. Supplementary CrProp did not affect
these indices in rats fed high-fat diets (Table 4).
The morphological structures of the liver and the kidney
are presented in Figs. 1 and 2. Feeding high-fat diets (40 %
energy from fat) led to the accumulation of lipid droplets in
hepatocytes but without symptoms of inflammation, necrosis,
or sclerotization in the glomerulus.
Neither the interstitium nor glomerulus of the kidney was
affected by feeding rats with a high-fat diet. Supplementary
CrProp slightly diminished liver lipid accumulation and did
not influence kidneymorphological structures in rats fed high-
fat diets.
Tissue Mineral Content
Feeding rats with a high-fat diet increased renal Fe content and
splenic Cu content by 29 and 16 %, respectively, but it did not
affect Zn and Cr contents in tissues in comparison with the
control (Table 5). Supplementary CrProp normalized or even
slightly decreased splenic Cu content, but it did not affect Fe,
Zn, or Cu levels in the other internal organs.
As it could have been expected, supplementary CrProp (10
and 50 mg Cr/kg diet), given in 5- and 25-fold higher dosages
than the control, increased tissular Cr contents; in the liver, it
increased by 48 and 105 %, respectively, while in the kidneys,
it increased by 196 and 444 %, respectively. The degree of the
increase of Cr content in internal organs was moderate, and
kidneys were the main target tissue.
Discussion
A number of studies both on diabetic animals and diabetic
patients reported that Cr(III) supplementation may be benefi-
cial, as evidenced by a decreased blood glucose, glycosylated
hemoglobin, and cholesterol values or decreased insulin re-
quirements after chromium supplementation [11, 13, 26–29].
On the other hand, there are also clinical trials showing that
supplementary Cr(III) did not improve significantly blood
biochemistry indices [30–33]. The exact mechanism of Cr
action has not been fully elucidated to date.
Table 2 Effect of CrProp supplementation on overall growth indices in rats (mean±SD)
Index Experimental group
C HF HF+Cr10 HF+Cr50
Food intake (g/day) 20.86±1.59 19.19±0.49 19.09±0.49 18.87±1.74
Body mass gain (g)/56 days 210±21 245±29 252±18 250±28
Body mass/body length ratio (g/cm) 17.3±1.23 a 19.0±0.91 b 18.6±0.81 b 18.3±1.32 b
Liver (% b.m.) 2.86±0.16 2.99±0.29 2.88±0.18 2.80±0.09
Kidneys (% b.m.) 0.61±0.07 0.60±0.07 0.55±0.03 0.57±0.03
Spleen (% b.m.) 0.16±0.02 0.15±0.02 0.17±0.02 0.17±0.03
Heart (% b.m.) 0.29±0.02 0.29±0.04 0.32±0.01 0.30±0.03
Testes (% b.m.) 0.85±0.10 0.90±0.14 0.89±0.11 0.90±0.08
Pancreas (% b.m.) 0.33±0.05 0.32±0.03 0.33±0.05 0.37±0.05
Means on the same line without a common lowercase letter differ significantly (p<0.05)
C control (AIN-93G), HF high-fat fed, HF+Cr10 high-fat with Cr (10 mg/kg diet), HF+Cr50 high-fat with Cr (50 mg/kg diet)
Table 3 Effect of high-fat diet and supplemental CrProp on blood serum lipids indices in rats (mean±SD)
Parameter Experimental group
C HF HF+Cr10 HF+Cr50
Glucose (mmol/dm3) 8.01±0.76 8.35±0.67 8.27±0.75 8.09±0.71
Insulin (mU/dm3) 29.7±13.2 a 59.3±20.4 b 58.9±16.6 b 55.2±20.8 b
HOMA-IR 10.6±4.90 a 22.3±8.71 b 20.6±6.62 b 20.3±8.44 b
Total cholesterol (mmol/dm3) 2.49±0.33 2.36±0.24 2.39±0.28 2.23±0.25
HDL cholesterol (mmol/dm3) 1.69±0.23 1.64±0.14 1.59±0.17 1.52±0.25
LDL cholesterol (mmol/dm3) 0.43±0.09 0.37±0.04 0.38±0.05 0.38±0.08
Triacylglycerols (mmol/dm3) 1.63±0.11 1.61±0.68 1.48±0.35 1.45±0.68
Table notes and abbreviations the same as in Table 2
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It is believed that the efficiency of supplementary Cr in the
regulation of disturbed glucose and lipid metabolism depends
on various factors, such as the chemical form and dose of Cr
(and its bioavailability), the degree of insulin resistance or
hyperglycemia, and individual sensitivity and genetics, which
are not fully defined factors.
The chromium(III) propionate complex (CrProp) was
found to be a promising insulin-activating agent, due to its
high stability and solubility in the physiological milieu and
high absorption rate reaching up to 40–60 % [8]. In a previous
study by a team of Vincent and coworkers [10], this com-
pound given to rats showed insulin-sensitizing properties.
Lower dosages of CrProp (20 μg/kg b.m./day) after a 12-
week administration resulted in lowering of blood plasma
LDL, total, and HDL cholesterol levels and triglyceride levels
in rats. In another study performed by that team [34], Zucker
obese rats (a model of the early stages of type 2 diabetes),
CrProp lowered fasting plasma total, HDL, and LDL choles-
terol, triglyceride concentrations, as well as insulin levels, and
it lowered 2-h plasma insulin levels after 24 weeks of admin-
istration. On the other hand, this compound had little effect on
rats with streptozotocin (STZ)-induced diabetes (a type 1
diabetes model). These results were further confirmed by
Clodfelder et al. [9], who applied higher dosages of CrProp
(up to 1,000 μg Cr/kg b.m./day) in healthy and type 2 diabetic
rats. It is worth noting that this study was conducted on rats,
where the metabolic changes associated with diabetes were
induced pharmacologically or by genetic engineering. In those
models, hyperglycemia and insulin resistance were more pro-
nounced; thus, the effects of CrProp were also more
pronounced.
In this study, we tested the preventive potential of supple-
mentary Cr, given in the form of CrProp, against insulin
resistance in Wistar rats. There are different ways of inducing
insulin resistance and diabetes in experimental animals, in-
cluding genetic modification (e.g., obese animals), pharmaco-
logic intervention (e.g., STZ and alloxan injection), dietary
manipulation (e.g., high-fat and high-fructose diets), and their
combinations (e.g., high-fat feeding and STZ injection). Some
studies [35] showed that a high-fat diet (~65 % calories from
fat) is more effective than a high-fructose diet (~65 % calories
from fructose) in inducing insulin resistance in Wistar rats.
The impact of different fat types on glucose and lipid-
related parameters was excessively studied by Buetner et al.
[36]. Those authors confirmed that the rats administered a 12-
week lard-based high-fat diet (approximately 42 % energy
from fat) gave symptoms resembling the human metabolic
Table 4 Effect of high-fat diet and supplemental CrProp on blood
toxicity markers in rats (mean±SD)
Blood index Experimental group
C HF HF+Cr10 HF+Cr50
ALT (U/dm3) 19.0±2.32 23.6±6.32 23.3±3.41 20.5±1.91
AST (U/dm3) 97.3±12.7 100.2±15.9 107.0±9.9 98.3±10.8
Total protein
(10−2 kg/dm3)
6.44±0.37 6.38±0.29 6.17±0.15 6.15±0.20
Creatinine
(μmol/dm3)
36.2±3.52 36.2±3.51 35.4±0 36.2±3.54
Urea (mmol/dm3) 5.63±0.77 4.75±0.93 4.25±0.37 4.39±0.52
Abbreviations the same as in Table 2
C HF
HF+Cr10 HF+Cr50
Fig. 1 Histopathological images of rats’ livers (zoom ×750): C—control
group, HF—group fed high-fat diet, HF+Cr10—group fed high-fat diet
supplemented with 10 mg Cr/kg diet, and HF+Cr50—group fed high-fat
diet supplemented with 50 mg Cr/kg diet
C HF
HF+ Cr10 HF+ Cr50
Fig. 2 Histopathological images of rats’ kidney (zoom ×750): C—con-
trol group, HF—group fed high-fat diet, HF+Cr10—group fed high-fat
diet supplemented with 10 mg Cr/kg diet, and HF+Cr50—group fed
high-fat diet supplemented with 50 mg Cr/kg diet
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syndrome, i.e., obesity, adiposity, an increased insulin resis-
tance index (HOMA-IR), or decreased serum adiponectin
levels, but not inflammation. Another way of inducing insulin
resistance is feeding animals a high-fructose diet (up to 60%),
which leads to increased adiposity and free fatty acid contents
in adipose tissues [37], hypertension, oxidative stress, in-
creased hydrogen peroxide generation, and inflammation
[38–40]. Generally, both animal models of insulin resistance
appear to be suitable for testing insulin-sensitizing agents.
In the present study, we used a high-fat diet to induce
insulin resistance in rats. There are significant differences in
lipid metabolism in rats and humans. These rodents show
higher tolerance to excessive fat consumption in comparison
to human subjects; however, this method seems more natural
in mimicking the process that occurs in humans than the
pharmacologic intervention.
Forbes et al. [41] investigated the effect of different diets,
which could be classified as Western diets, on insulin resis-
tance. It was found that excessive consumption of saturated
animal origin fat increased body mass and adiposity, de-
creased insulin sensitivity, and impaired skeletal muscle insu-
lin signaling and insulin hypersecretion. The observed effect
depends not only on the total amount of fat, but first of all, on
the fatty acid composition of dietary components [36]. High-
fat diet induces liver steatosis and disturbs iron metabolism in
rats [42].
In the last few years, several publications appeared regarding
the influence of supplementation with Cr(III) compounds on
high-fat-fed animals. For example, Sahin et al. [43] compared
the effects of two Cr(III) compounds, i.e., Cr glycinate (CrGly)
and Cr acetate (CrAc), given at dosages of 4 and 8 μg/kg b.m./
day on Wistar rats fed high-fat diets. It was found that animals
receiving CrGly had greater serum insulin concentrations (by
3.0 %), while those treated with CrAc had lower serum glucose
concentrations (by 1.7 %) as well as the glucose/insulin ratio
(by 4.49 %). Similar results were observed for Cr(III)
histidinate (CrHis) [44].
Kandadi et al. [45] reported that supplementary chromium
(D-phenylalanine)3 (45 μg Cr/kg b.m./day) had no effect on
food intake and body and organ masses, but it normalized
serum glucose, insulin, and triglyceride levels in C57BL/6
mice fed high-fat diets.
Chen et al. [46] studied the effect of supplementary Cr-
containing milk concentrate capsule (80 μg/kg b.m./day) and
high-fat diets (67 % of calories provided by fat) on KK/
HIJ mice. It was found that supplementary Cr reduced
the hepatic triglyceride accumulation, elevated hepatic
lipid catabolic enzymes, improved liver histopathologi-
cal changes, and suppressed inflammation as well as
oxidative stress. Similar improvements in liver histology
were also observed by Sahin et al. [47] in high-fat diet
fed/STZ-injected Sprague–Dawley rats supplemented
with Cr(III) picolinate (80 μg/kg b.m.). In this study,
CrProp supplementation tended to decrease relative liver
mass and serum triglyceride concentration and slightly
improved liver histopathological changes caused by
high-fat feeding. These results suggest that this com-
pound slightly inhibits the liver steatosis; however, the
liver triglyceride content was not determined, and there-
fore, it needs to be confirmed in a further study.
Table 5 Effect of high-fat diet and supplemental CrProp on the tissular iron, zinc, copper, and chromium levels in rats (mean±SD)
Index Experimental group
C HF HF+Cr10 HF+Cr50
Fe (μg/g dry matter (d.m.))
Liver 359±43.1 372±53.3 339±47.4 393±61.0
Kidney 280±40.1 a 360±49.01 b 379±35.2 b 363±39.1 b
Spleen 2,560±517 2,551±538 2,597±198 2,765±594
Zn (μg/g d.m.)
Liver 90.1±4.25 96.6±8.12 90.2±9.23 96.9±6.03
Kidney 86.7±3.55 92.2±5.91 93.8±7.65 96.1±6.47
Spleen 41.37±4.26 41.45±7.24 46.04±3.02 48.05±4.08
Cu (μg/g d.m.)
Liver 15.3±2.91 15.8±0.63 13.7±1.45 15.9±0.81
Kidney 20.1±2.13 24.6±4.32 24.6±4.78 24.4±4.23
Spleen 8.35±2.79 a 9.67±3.25 b 6.01±0.95 a 6.06±1.00 a
Cr (μg/g d.m.)
Liver 0.62±0.18 a 0.58±0.21 a 0.92±0.53 ab 1.19±0.64 b
Kidney 0.46±0.17 a 0.52±0.23 a 1.54±0.7 b 2.83±0.58 c
Table notes and abbreviations the same as in Table 2
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In our previous studies [11, 12], insulin resistance was
induced by feeding rats for 8 weeks a high-fructose diet
(60 % fructose w/w) and a high-fat diet (40 % calories) and
by STZ injection (35 mg/kg b.m.). However, these models
gave different degrees of metabolic changes in terms of insulin
resistance and related effects in rats.
In particular, the first treatment induced insulin resistance
without hyperglycemia (HOMA-IR index increased by
230 %, with only a slight increase of serum glucose by
16 %), while the latter model resulted in insulin resistance
(HOMA-IR index increased by 130 %) with hyperglycemia
(serum glucose increased by 170%). The therapeutic potential
of CrProp, given at the dosages of 1 and 5 mg Cr/kg b.m./day,
was then tested on those models. It was found that in high-
fructose-fed rats, supplementary CrProp in both dosages was
able to significantly decrease serum insulin levels and insulin
resistance indexes HOMA-IR and HOMA-B, while it in-
creased the QUICKI insulin sensitivity index. Also, in high-
fat/STZ rats, CrProp, especially given in a higher dosage, was
more effective in improving those indices. The efficiency of
supplementary Cr depended, among other factors, on the
degree of metabolic disturbances occurring in the organism,
in the following mode: the higher the degree of insulin resis-
tance or hyperglycemia, the stronger the effect of Cr, which
suggests its pharmacological action.
This statement falls in agreement with the observations that
supplementary Cr, no matter what chemical form or dosage is
applied, has no effect on a healthy organism, both in animals
and humans. Recently, Herring et al. [48] studied the same Cr
compound (Cr3 or CrProp) in healthy rats fed cafeteria-style
diets (high-fat and high-carbohydrate diets) in a long exposure
experiment. After a 15-month feeding of rats using those diets,
CrProp at a dosage of 1 mg/kg b.m./day had no effect on body
mass, organ masses (liver, kidneys, lungs, and heart), or
visceral fat mass. In the present study, the calculated average
daily Cr intake in experimental CrProp-supplemented groups
was 0.58 and 2.85 mg Cr/kg b.m./day, respectively (based on
the daily food intake, analyzed Cr content in the diet, and
weekly body gain).
Cr in its trivalent form can interact in vivo with other
essential elements, especially with Fe. The Fe–Cr interaction
may occur, since these elements have the same transport
protein, transferrin. The relationship between an increased
dietary Cr(III) intake and Fe stores was confirmed in several
studies. For example, in our previous study, 8-week CrProp
supplementation (1 mg Cr/kg b.m./day) decreased Fe kidney
concentration [11]; in contrast, a 4-week administration of
CrProp in the same dosages did not influence the examined
parameters of iron status in rats fed a high-fructose diet [49].
In obese type 2 diabetic rats, supplementation of 1,000 μg Cr/
kg b.m./day in the form of CrProp reduced kidney Fe level
[12]. Consistent results were observed for the same dosages
used in another experiment, where CrProp normalized an
increased liver Fe content in rats fed high-fat diets/STZ-
injected rats [12]. On the other hand, another Cr complex,
CrHis, did not change tissular Fe concentration in a similar
animal model of type 2 diabetes after 10 weeks of supplemen-
tation [50].
The effects of different Cr compounds on mineral metab-
olism have been extensively investigated by Staniek et al.
[51]. In that comparative study, supplementary Cr
(1 mg/kg b.m./day), given in the form of CrProp or CrCl3
for 12 weeks, significantly increased Cr accumulation in
kidneys of lean and obese but not Zucker diabetic rats. Gen-
erally, there were no changes in tissular contents of Ca, Mg,
Fe, and Zn, except for Cu, in rats.
Similarly, supplementary CrProp affected Cu levels in rats
fed a high-fructose diet for 4 or 8 weeks. In particular, this
compound normalized elevated liver and splenic Cu contents
[11, 49], while it decreased hepatic and renal Cu levels in
diabetic rats [12].
In conclusion, this study showed that supplementary
CrProp, given in the dosages of 10 and 50 mg Cr/kg diet
(approximately 0.6 and 3 mg Cr/kg b.m./day, respectively), is
not able to prevent insulin resistance induced by feeding rats
with a high-fat diet.
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